PD
Therapeutic Areas
Apellis Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pegcetacoplan (Systemic) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Approved |
| Pegcetacoplan (Intravitreal) - SYFOVRE | Geographic Atrophy (GA) Secondary to AMD | Approved |
| Pegcetacoplan (Intravitreal) | Geographic Atrophy (GA) Secondary to AMD (Japan) | Phase 3 |
| APL-3007 | Undisclosed Ophthalmology Indication | Discovery/Preclinical |
| Undisclosed Programs | Neurological Diseases | Research |
Leadership Team at Apellis Pharmaceuticals
CF
Cedric Francois
Co-Founder, Chief Executive Officer & President
CB
Caroline Baumal
Chief Medical Officer
KB
Kelley Boucher
Chief People Officer
MD
Mark DeLong
Chief Business & Strategy Officer
LM
Leslie Meltzer
Chief Research & Development Officer
NN
Nur Nicholson
Chief Technical Operations Officer
TS
Timothy Sullivan
Chief Financial Officer
DW
David Watson
General Counsel
GC
Gerald Chan
Chairman of the Board
MD
Mikael Dolsten
Director